复星医药：膦甲酸钠注射液获注册批准

Core Viewpoint - Fosun Pharma (600196.SH) announced that its subsidiary, Guilin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the drug registration application of Sodium Foscarnet Injection, which is indicated for the treatment of (1) cytomegalovirus retinitis in AIDS patients and (2) acyclovir-resistant mucocutaneous infections in immunocompromised patients [1] Group 1 - The drug approval expands the treatment options for AIDS patients suffering from cytomegalovirus retinitis [1] - The approval also addresses the needs of immunocompromised patients facing acyclovir-resistant infections [1]